Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY
Alnylam shares fell 6.7% to $370.91 after preliminary fourth-quarter sales for Amvuttra missed Wall Street estimates. The company reported about $827 million in Amvuttra revenue, below analyst expectations of $852 million. Alnylam set 2026 product revenue guidance at $4.9 billion to $5.3 billion and outlined a new five-year plan. Full results are due in February.